FDA Grants Breakthrough Therapy Designation for Elsunersen (PRAX-222) for SCN2A-DEE
PRAX has more than doubled off its 52-week low of $37.19.
Summary
Praxis Precision Medicines announced that the FDA has granted Breakthrough Therapy Designation for elsunersen (PRAX-222), a drug for seizures associated with SCN2A Developmental and Epileptic Encephalopathy (DEE). This designation expedites the drug's development and regulatory review.
Key Events · Product Development and Regulatory · PRAX
-
Breakthrough Therapy Designation Received
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for elsunersen (PRAX-222).
-
Target Condition: SCN2A-DEE
Elsunersen is an antisense oligonucleotide intended for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopathy (DEE) caused by Gain of Function variants in SCN2A.
-
Expedited Development and Review
BTD enables expedited development and regulatory review for drugs treating serious conditions with preliminary evidence of substantial clinical improvement over existing therapies.
-
Supported by Positive Trial Results
The BTD was supported by positive topline results from the EMBRAVE Part A trial, a Phase 1/2 study in pediatric patients with early-seizure-onset SCN2A-DEE.
Analysis · PRAX · Life Sciences
The FDA's Breakthrough Therapy Designation for elsunersen significantly accelerates its development and regulatory review process. This designation is granted when preliminary clinical evidence suggests a drug may offer substantial improvement over existing therapies for a serious condition, indicating a faster path to market and potential for earlier revenue generation for Praxis Precision Medicines.
At the time of this filing, PRAX was trading at $303.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.5B. The 52-week trading range was $37.19 to $366.52. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.